ESRRA and breast neoplasm: Importantly, the inhibition of ERRα significantly reduced HIF-1α activity and reversed doxorubicin efflux typical of the MDR phenotype, providing strong support for the targeting of ERRα in hypoxia-driven, chemoresistant breast tumors.